Caricamento...
A novel modified RANKL variant can prevent osteoporosis by acting as a vaccine and an inhibitor
BACKGROUND: The discovery of receptor activator of nuclear factor‐ĸB ligand (RANKL) as the final effector in the pathogenesis of osteoporosis has led to a better understanding of bone remodeling. When RANKL binds to its receptor (RANK), osteoclastic differentiation and activation are initiated. Here...
Salvato in:
| Pubblicato in: | Clin Transl Med |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
John Wiley and Sons Inc.
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7967917/ https://ncbi.nlm.nih.gov/pubmed/33784004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ctm2.368 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|